Trastuzumab Biosimilar on Par With Reference Product in Early Breast Cancer Trastuzumab Biosimilar on Par With Reference Product in Early Breast Cancer

Safety, efficacy and clinical outcomes were similar for Amgen ' s trastuzumab biosimilar ABP 980 and the trastuzumab reference product in women with HER2-positive early breast cancer in the LILAC study, researchers reported June 4 at the 2018 ASCO Annual Meeting.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news